GlassScriptPhysician profile
Gregory J Lindsay
NPI 1942416607
$753.08
in general payments reported to CMS, 2019-2025
15 companies · $96.87 in 2025
The $96.87 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.90 · 2023: $441 · 2024: $198 · 2025: $96.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $156.14 | 2023-2024 | Amyvid, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $105.50 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $85.09 | 2023-2024 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $69.35 | 2023-2025 | |
| Pfizer INC. | $59.09 | 2023 | |
| Sanofi-Aventis U.S. LLC | $47.26 | 2023-2024 | |
| Dexcom, INC. | $46.98 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.66 | 2025 | Jardiance |
| Mannkind Corporation | $30.25 | 2023 | Afrezza |
| Medtronic, INC. | $23.75 | 2025 | Symplicity G3 |
| Ascensia Diabetes Care US INC. | $21.72 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $20.94 | 2023 | Inpefa |
| Abbvie INC. | $19.95 | 2024 | |
| Amgen INC. | $19.31 | 2023 | Aimovig |
| Astrazeneca Pharmaceuticals LP | $15.09 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lindsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.